7 April 2022
Proveca announces agreement with Biopas Laboratories
Proveca Ltd is excited to announce a significant agreement outside Europe with Biopas Laboratories based in Colombia. Biopas will commercialise and distribute Sialanar® exclusively throughout Spanish speaking territories in South America.
Under the terms of the agreement, Biopas will have exclusive rights to distribute, market, and seek reimbursement for Sialanar® within its paediatric indication in Argentina, Chile, Ecuador, Peru, Panama, Costa Rica, Colombia and Mexico. It is estimated that approximately 19,000 children with neurodisabilities suffer today from sialorrhoea in this Latin American region.
Sialanar® (320 mcg/ml glycopyrronium, oral solution) received a European Paediatric Use Marketing Authorisation (PUMA) on 15th September 2016 for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Sialanar®® is being used to treat children across most countries in Europe and the UK.
Dr Simon Bryson, CEO and founder of Proveca Ltd, commented: “We are delighted to announce this agreement with Biopas to make Sialanar® available to children with neurodisabilities who suffer from sialorrhoea. As in many countries across the world there is a high unmet need to manage this condition and improve the quality of the lives of patients and their carers. We are looking forward to working with Biopas who can offer their first-class capabilities to support the launch of Sialanar®® in the Latin American region. This is a significant agreement outside the EU for Sialanar® as part of our commercialisation strategy to optimise access of our products across the world”
Pascal Forget, CEO and Co-Founder of Laboratoires Biopas, commented: “This significant partnership will allow Biopas and Proveca Ltd to actively pursue their mission of providing highly innovative products to cover unmet medical needs for patients in the Latin American region. The partnership further strengthens and consolidates Biopas CNS portfolio and its robust and strategic regional leadership’s position, allowing Biopas to provide new treatment options not previously available in Latin America to paediatric patients."